Telix Pharmaceuticals (TLPPF) Non-Current Assets (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Non-Current Assets for 4 consecutive years, with $873.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets changed N/A year-over-year to $873.8 million in Q2 2026; TTM through Dec 2025 was $6.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $6.9 million, up 537.92% from the prior year.
• Non-Current Assets was $873.8 million for Q2 2026 at Telix Pharmaceuticals, up from $6.9 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $873.8 million in Q2 2026 and troughed at $6.9 million in Q4 2025.
• A 4-year average of $346.2 million and a median of $251.9 million in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets surged 246.25% in 2024 and tumbled 98.23% in 2025, its largest moves.
• Over 4 years, Non-Current Assets stood at $112.9 million in 2023, then surged by 246.25% to $391.0 million in 2024, then plunged by 98.23% to $6.9 million in 2025, then surged by 12536.73% to $873.8 million in 2026.
• The last three Non-Current Assets figures came in at $873.8 million (Q2 2026), $6.9 million (Q4 2025), and $391.0 million (Q4 2024), per Business Quant data.